GB2380130A - Antioxidant compositions for companion animals - Google Patents
Antioxidant compositions for companion animals Download PDFInfo
- Publication number
- GB2380130A GB2380130A GB0227967A GB0227967A GB2380130A GB 2380130 A GB2380130 A GB 2380130A GB 0227967 A GB0227967 A GB 0227967A GB 0227967 A GB0227967 A GB 0227967A GB 2380130 A GB2380130 A GB 2380130A
- Authority
- GB
- United Kingdom
- Prior art keywords
- dog
- cat
- vitamin
- foodstuff
- 400kcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 110
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 103
- 241001465754 Metazoa Species 0.000 title claims description 55
- 239000000203 mixture Substances 0.000 title description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 225
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 183
- 241000282326 Felis catus Species 0.000 claims abstract description 177
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 111
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 110
- 229940046009 vitamin E Drugs 0.000 claims abstract description 110
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 110
- 239000011709 vitamin E Substances 0.000 claims abstract description 110
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 109
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 95
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 79
- 239000011718 vitamin C Substances 0.000 claims abstract description 79
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 78
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 78
- 229960003080 taurine Drugs 0.000 claims abstract description 47
- 230000036542 oxidative stress Effects 0.000 claims abstract description 30
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 24
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 24
- 239000011648 beta-carotene Substances 0.000 claims abstract description 24
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 24
- 229960002747 betacarotene Drugs 0.000 claims abstract description 24
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 24
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 20
- 235000012680 lutein Nutrition 0.000 claims abstract description 16
- 239000001656 lutein Substances 0.000 claims abstract description 16
- 229960005375 lutein Drugs 0.000 claims abstract description 16
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 16
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 16
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 15
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 235000005911 diet Nutrition 0.000 claims description 123
- 230000037213 diet Effects 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 53
- 235000021466 carotenoid Nutrition 0.000 claims description 40
- 150000001747 carotenoids Chemical class 0.000 claims description 40
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 31
- 239000013589 supplement Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 17
- 239000001751 lycopene Substances 0.000 claims description 17
- 229960004999 lycopene Drugs 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 17
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 16
- 235000012661 lycopene Nutrition 0.000 claims description 16
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 16
- 229940087168 alpha tocopherol Drugs 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 230000001900 immune effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229960000984 tocofersolan Drugs 0.000 claims description 12
- 235000004835 α-tocopherol Nutrition 0.000 claims description 12
- 239000002076 α-tocopherol Substances 0.000 claims description 12
- 238000002255 vaccination Methods 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001010 compromised effect Effects 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 137
- 210000002381 plasma Anatomy 0.000 description 122
- 238000003556 assay Methods 0.000 description 33
- 230000009469 supplementation Effects 0.000 description 33
- 239000000047 product Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 21
- 235000013305 food Nutrition 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 18
- 230000000378 dietary effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 14
- 108010012715 Superoxide dismutase Proteins 0.000 description 14
- 102000008857 Ferritin Human genes 0.000 description 12
- 108050000784 Ferritin Proteins 0.000 description 12
- 238000008416 Ferritin Methods 0.000 description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 12
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 11
- 240000003768 Solanum lycopersicum Species 0.000 description 11
- 235000020940 control diet Nutrition 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 241000282465 Canis Species 0.000 description 10
- 239000011732 tocopherol Substances 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 235000005881 Calendula officinalis Nutrition 0.000 description 9
- 108010075016 Ceruloplasmin Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 240000000785 Tagetes erecta Species 0.000 description 9
- 229960005070 ascorbic acid Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000003908 quality control method Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 102100023321 Ceruloplasmin Human genes 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 8
- 229930003799 tocopherol Natural products 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229960001295 tocopherol Drugs 0.000 description 7
- 229940042585 tocopherol acetate Drugs 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 6
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- -1 lipid hydroperoxides Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000004792 oxidative damage Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000021195 test diet Nutrition 0.000 description 6
- 241000282324 Felis Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241000824799 Canis lupus dingo Species 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002540 palm oil Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930003802 tocotrienol Natural products 0.000 description 4
- 239000011731 tocotrienol Substances 0.000 description 4
- 235000019148 tocotrienols Nutrition 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000010930 zeaxanthin Nutrition 0.000 description 4
- 239000001775 zeaxanthin Substances 0.000 description 4
- 229940043269 zeaxanthin Drugs 0.000 description 4
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 3
- 241001677259 Acanthophoenix rubra Species 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 208000000655 Distemper Diseases 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 240000004658 Medicago sativa Species 0.000 description 3
- 235000010624 Medicago sativa Nutrition 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 239000011795 alpha-carotene Substances 0.000 description 3
- 235000003903 alpha-carotene Nutrition 0.000 description 3
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008723 osmotic stress Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 229940068778 tocotrienols Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000020782 vitamin E status Nutrition 0.000 description 3
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 2
- 241000714201 Feline calicivirus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical class OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 235000019728 animal nutrition Nutrition 0.000 description 2
- 230000003263 anti-adenoviral effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000021048 nutrient requirements Nutrition 0.000 description 2
- 230000031787 nutrient reservoir activity Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 229940097156 peroxyl Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 125000001020 α-tocopherol group Chemical group 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 238000000846 Bartlett's test Methods 0.000 description 1
- RAFGELQLHMBRHD-VFYVRILKSA-N Bixin Natural products COC(=O)C=CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)O)/C)C RAFGELQLHMBRHD-VFYVRILKSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 239000004217 Citranaxanthin Substances 0.000 description 1
- SLQHGWZKKZPZEK-JKEZLOPUSA-N Citranaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)C)C=CC=C(/C)C=CC1=C(C)CCCC1(C)C SLQHGWZKKZPZEK-JKEZLOPUSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 208000001649 Pica Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- RAFGELQLHMBRHD-UHFFFAOYSA-N alpha-Fuc-(1-2)-beta-Gal-(1-3)-(beta-GlcNAc-(1-6))-GalNAc-ol Natural products COC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC(O)=O RAFGELQLHMBRHD-UHFFFAOYSA-N 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 239000001670 anatto Substances 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- RAFGELQLHMBRHD-SLEZCNMESA-N bixin Chemical compound COC(=O)\C=C\C(\C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O RAFGELQLHMBRHD-SLEZCNMESA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019247 citranaxanthin Nutrition 0.000 description 1
- PRDJTOVRIHGKNU-ZWERVMMHSA-N citranaxanthin Chemical compound CC(=O)\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C PRDJTOVRIHGKNU-ZWERVMMHSA-N 0.000 description 1
- PRDJTOVRIHGKNU-UHFFFAOYSA-N citranaxanthine Natural products CC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C PRDJTOVRIHGKNU-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000020796 iron status Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000005839 radical cations Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940046664 taurine 500 mg Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 239000011723 β-tocotrienol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Abstract
The present invention utilizes an antioxidant cocktail to overcome the problem of oxidative stress in a cat or dog. Such cocktail is used to boost immunological response. The cocktail comprises Vitamin E, beta-carotene and lutein. Vitamin C and taurine may also be present.
Description
<Desc/Clms Page number 1>
Antioxidant Compositions and Methods for Companion Animals Free radicals are inherent in the aerobic metabolism of living organismes and are generated by both physiological and pathological processes. They are sometimes generated intentionally to serve biological functions, such as microbicides in phagocyte cells, or may be accidents of chemistry following which they exhibit destructive behaviours. Whatever their mechanism of generation, if free radical production and removal is not controlled, then their effects on an organism can be damaging. To combat excessive and inappropriate damage, an elaborate system of antioxidant defences has evolved.
When there is an unbalance between the oxidants and the antioxidants II1 favour of the
oxidants, a condition of oxidative stress exists that can lead to tissue damage. xi o The present invention provides, amongst others, a means to overcome the problem of oxidative stress in the domestic cat and dog. oxi I I I Accordingly, a first aspect of the invention provides a method for increasing the plasma vitamin E level in a domesticated cat or dog, the method comprising the step of administering to said cat or dog, an amount of vitamin E sufficient to increase the plasma vitamin E level. The increase may be to the maximum/saturation point measurable in the plasma of the animal. The increase may be in the range of 2 to 3 times the animal's own base line for plasma vitamin E levels (around the maximum physiological increase). The increase may be measured as an increase in the plasma vitamin E level of up to 25%, preferably 25% or above (preferably up to 50%, or 25 to 50%, or even 50 to 90%) of an individual animal when compared to the plasma vitamin E level when the animal is fed a control diet. The control diet, for example, is such that the total vitamin E consumption for the cat or dog is 10IJ/400kcal.
<Desc/Clms Page number 2>
Vitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity. The most biologically active biological form of vitamin E (also the most active antioxidant) in animal tissue is alpha-tocopherol. Vitamin E cannot be synthesised in vivo. Vitamin E protects against the loss of cell membrane integrity, which adversely alters cellular and organelle function.
Units of vitamin E can be expressed as International Units (fU), where 1 IU of alphatocopherol equals 1 mg of alpha-tocopherol. Other vitamin E compounds have their IU determined by their biopotency in comparison to alpha-tocopherol as described in McDowell, L. R (1989) Vitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.
To date, levels of vitamin E above and beyond the minimum levels sufficient to prevent vitamin E deficiency symptoms present in the domestic dog or cat have not been of interest. This invention identifies that the levels of vitamin E in the dog or cat reflect the levels present in their diet and that these levels provide a typical baseline level (see examples) which is not exceeded when the animal is fed on prepared petfood. The present invention shows that the levels of vitamin E in the dog and cat can be increased by incorporating higher levels of vitamin E in the animal's diet (and that this can be achieved by the provision of specialised prepared petfood and/or a cat or dog supplement).
Aspects of the invention provide a means for reducing oxidative stress in the domestic cat and dog. Such a reduction in oxidative stress, in particular strengthens the immune response and provides a healthier animal. Markers of oxidative damage in a dog or cat include, amongst others: plasma carbonyls (end products of protein oxidation), plasma lipid hydroperoxides (markers of lipid oxidation), and anti-LDL antibodies which are produced as a response to LDL oxidation. A decline in any of these is indicative of reduced oxidative damage.
<Desc/Clms Page number 3>
The vitamin E according to the first aspect of the invention may be in any form. It may be a tocopherol or a tocotrienol. It may be alpha-tocopherol, (d-a or dl-a) betatocopherol (d-ss or dl-ss), gamma-tocopherol (d-y or dl-y), delta-tocopherol, alphatocotrienol, beta-tocotrienol, gamma-tocotrienol or delta-tocotrienol. Preferably it is alpha-tocopherol.
The source of the vitamin E is not limiting. Preferred vitamin E sources include vitamin E acetate, (e. g tocopherol acetate), vitamin E acetate adsorbate or vitamin E acetate spray dried. Preferred sources are synthetic although natural sources may be used.
The form of administration of the vitamin E is not limiting. It may be in the form of a z : l diet, foodstuff or a supplement. Hereinafter in this text, the term"foodstuff covers all of foodstuff, diet and supplement. Any of these forms may be solid, semi-sold or liquid.
The supplement is particularly useful to supplement a diet or foodstuff which does not contain sufficiently high levels of one or more of the components according to the invention. The concentrations of the components in the supplement may be used to "top up"the levels in the animal's diet or foodstuff. This can be done by including a quantity of the supplement with the animal's diet or by additionally feeding the animal a quantity of the supplement. The supplement can be formed as a foodstuff with extremely high levels of one or more components of the invention which requires dilution before feeding to the animal. The supplement may be in any form, including solid (e. g. a powder), semi-solid (e. g. a food-like consistency/gel), a liquid or alternatively, it may be in the form of a tablet or capsule. The liquid can conveniently be mixed in with the food or fed directly to the animal, for example via a spoon or via a pipette-like device. The supplement may be high in one or more components of the
<Desc/Clms Page number 4>
invention or may be in the form of a combined pack of at least two parts, each part containing the required level of one or more component.
Preferably the vitamin E is incorporated into a commercial petfood product or a commercial dietary supplement. The petfood product may be a dry, semi-dry, a moist or a liquid (drink) product. Moist products include food which is sold in tins or foil containers and has a moisture content of 70 to 90%. Dry products include food which have a similar composition, but with 5 to 15% moisture and presented as biscuit-like kibbles. The diet, foodstuff or supplement is preferably packaged. In this way the consumer is able to identify, from the packaging, the ingredients in the food and identify that it is suitable for the dog or cat in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic, paper or card. The amount of moisture in any product may influence the type of packaging which can be used or is required.
The foodstuff according to the present invention encompasses any product which a dog or cat may consume in its diet. Thus, the invention covers standard food products, as well as pet food snacks (for example snack bars, biscuits and sweet products). The foodstuff is preferably a cooked product. It may incorporate meat or animal derived material (such as beef, chicken, turkey, lamb, blood plasma, marrowbone etc, or two or more thereof). The foodstuff alternatively may be meat free (preferably including a meat substitute such as soya, maize gluten or a soya product) in order to provide a protein source. The product may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The product may also contain a starch source such as one or more grains (e. g. wheat, corn, rice, oats, barely etc) or may be starch free. A typical dry commercial dog and cat food contains about 30% crude protein, about 10-20% fat and the remainder being carbohydrate, including dietary fibre and ash. A typical wet, or moist product contains (on a dry matter basis) about 40% fat, 50% protein and the remainder being fibre and ash. The present invention is
<Desc/Clms Page number 5>
particularly relevant for a foodstuff as herein described which is sold as a diet, foodstuff or supplement for a cat or dog.
In the present text the terms"domestic"dog and"domestic"cat mean dogs and cats, in particular Felis domesticus and Canis domesticus.
The level of plasma vitamin E in a cat or dog can easily be determined. A representative example of determining plasma vitamin E level is described in the introductory portion of the examples.
The concentration of vitamin E in a product (solid or liquid or any other form) can easily be determined. This is also described in the introductory portion of the examples.
In the first aspect of the invention, the control diet may, instead, provide a total vitamin E to the animal of 15TIJ/400kcaI.
Preferably, the administration of the vitamin E according to the first aspect of the invention is at a level of from 25IU/400kcal diet. Throughout this text, references to concentrations per kcal are to kcal total metabolisable energy intake. The determination of calorie density can be identified using Nutritional Requirements of Dogs (1985) National Research Council (U. S.) National Academy Press Washington DC, ISBN: 0-309-03496-5 or Nutritional Requirements of Cats (1986) National Research Council (U. S. ) National Academy Press Washington DC, ISBN: 0-309- 03682-8. Preferred levels for cats are from 30IU/400kcal, from 35IU/400kca1, from
40IU/400kcal, from 45IU/400 kcal, from 50IU/400 kcal, from 55IU/400kcal, up to about 100lU/400kcal or above. Preferred levels for dogs are from 30IU/400kcal, from 40IU/400kcal, from 45IU/400kcal, from 50IU/400kcal, from 55IU/400kcal, from 60IU/400kca1, from 65IU/400kcal, up to about from 100lU/400kcal or above.
<Desc/Clms Page number 6>
For the first aspect of the invention, the method may include the administration of an amount of vitamin C (ascorbic acid).
Vitamin C is a water-soluble substance. It is synthesised de novo in both the domestic cat and the domestic dog. Because it is synthesised in vivo, the effect of vitamin C supplements in dog and cat has not previously been investigated. In particular, the effect of vitamin C supplementation in cat and dog, as a potential antioxidant and in combination with vitamin E supplementation has not been investigated.
The present invention shows that vitamin C levels in a cat or a dog can be increased by supplementation. This is demonstrated by an increase in plasma values following vitamin C supplementation. The increase in vitamin C levels can contnbute to a reduction in free radicals and therefore a reduction in oxidative stress in the animal.
The vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid. Preferably it is a heat stable form such as a form of calcium phosphate.
The source of the vitamin C is not limiting-Preferred vitamin C sources include crystalline ascorbic acid (optionally pure), ethylcellulose coated ascorbic acid, calcium phosphate salts of ascorbic acid, ascorbic acid-2-monophosphate salt or ascorbyl-2monophosphate with small traces of the disphosphate salt and traces of the triphophate salt, calcium phosphate, or for example, fresh liver.
The level of vitamin C in a product (solid, liquid or any other form) can easily be determined. This is described in the introductory part of the examples.
A further useful point in relation to the use of vitamin E in combination with vitamin C is their potential to act synergistically. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in
<Desc/Clms Page number 7>
the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol. The preferred concentration of vitamin C according to the first aspect of the invention is a level which preferably increases the plasma vitamin C level of an animal by up to about 25% (preferably 25% or more) in comparison with when the animal is fed a control diet, such that its total vitamin C consumption is (for both a cat or a dog) 5mg/400kcal diet. Levels of vitamin C which do not achieve this increase are still covered by the first aspect of the invention. Levels of vitamin C according to the first aspect of the invention include from 10, 12,15, 17, 20,22, 25,27, 30,32, 38,40, 42, 48 up to about 50 mg/400kcal diet. Preferred levels for the cat are the above options from 10 to 48 mg/400kcal and for the dog, the above options from 12 to 50 mg/400kcaI. Levels above 55 mg/400kcal provide no added benefit and are usually best avoided.
The first aspect of the invention may include the administration of an amount of taurine. The taurine may be in addition to, or instead of, the supplemented vitamin C described above.
Taurine is an unusual amino acid found in a wide variety of animal species. Taurine is an essential nutrient for the cat which, unlike the dog, is unable to synthesise taurine from precursor amino acids. It is thought that taurine protects cellular membranes from toxic components including oxidants. The increase in vitamin taurine levels in an animal diet can contribute to a reduction in free radicals and therefore a reduction in oxidative stress in the animal, in particular in combination with the other components of the invention.
The taurine according to the first aspect of the invention may be in any form. It may be powered, crystalline, semi-solid or liquid.
<Desc/Clms Page number 8>
The source of the taurine is not limiting. Preferred taurine sources include aminoethylsulfonic acid (C2H7N03S). Sources may be natural or synthetic.
Suitable concentrations of taurine for use according to the first aspect of the invention are usually determined, to some extent as to the processing of the product (for example, whether the product is dry or canned). To maintain plasma taurine levels in the cat at the normal range ( > 60umoI/I), a canned (moist) diet must supply at least 39mg of taurine/kg body weight per day and a dry diet at least 19mg/kg body weight per day. The first aspect of an invention provides, for a product which is not subjected to a high temperature method (such as canning) a preferred level of from about 80mg/400kcal, more preferably from about 100, increasing even more preferably from 120,150, 180,200, 220,250, 280,300, 320,350, 400 and above in mg/400kcal diet.
In a product which is processed such as by high temperature, levels according to the invention are preferably from about 380mg/400kcal, more preferably from about 400, increasing even more preferably from 420, 450,480, 500, 520, 550,580, 600,620, 650, 700 and above in mg/400kcal diet.
The concentration of taurine in a product (solid liquid or in any other form) can be easily determined. A representative method is described in the introductory portion of the examples. The in vivo feline status of taurine can be enhanced through dietary supplementation. The dose response effect of dietary taurine content can be measured by plasma levels. This is also described in the introductory portion of the examples.
The first aspect of the invention may further include the administration of an amount of a carotenoid. The carotenoid may be in addition to, or instead of, the supplemented vitamin C and/or the taurine as described above.
The carotenoids are a group of red, orange and yellow pigments predominantly found in plant foods, particularly fruit and vegetables, and in the tissues of animals which eat the plants. They are lipophilic compounds. Some carotenoids act as a precursors of
<Desc/Clms Page number 9>
vitamin A, some cannot. This property is unrelated to their antioxidant activity. Carotenoids can act as powerful antioxidants. Carotenoids are absorbed in varying degrees by different animal species. Carotenoids may be classified into two main groups; those based on carotenes and those based on xanthophylls (which include oxygenated compounds). Common carotenoids include; beta-carotene, alphacarotene, lycopene, lutein, zeaxanthin and astaxanthin. Carotenoids are not proven to be essential nutrients in the feline or canine diet. Unlike humans and dogs, the cat is unable to convert the precursor beta-carotene into the active vitamin A form since the required enzyme necessary for this conversion is absent from the intestinal mucosa in cats (they do not possess the dioxygenase enzyme which is needed to cleave the carotene molecule).
This invention shows that carotenoids can be absorbed by the domestic cat and dog (to give an increased plasma concentration) and can contribute to a reduction in oxidative stress Further, the present invention has demonstrated that the carotenoids can be absorbed following their incorporation into a commercial product. As mentioned above, the components of the first aspect of the invention may act synergistically.
Vitamin E is able to protect beta-carotene from oxidation and may have a sparing effect on beta-carotene. Vitamin E is thought to protect the chemical bonds of betacarotene from being oxidised.
The source of the carotenoids is not limiting and can include natural and synthetic sources. In particular, the preferred source is a natural source and includes; marigold meal and lucerne meal (sources of lutein) ; tomato meal, red palm oil, tomato powder, tomato pomace/puip (sources of beta-carotene and lycopene). Sources include oils high in carotenoid levels and pure manufactured carotenoids such as lutein, violaxanthin, cryptoxanthin, bixin, zeaxanthin, apo-EE (Apo-8-carotenic acid ethylester), canthaxanthin, citranaxanthin, achinenone, lycopene and capsanthin.
Preferred levels of total carotenoids are from O. 01mg/400kcal, or from 0. 2mg/400kcal or from lmg/400kcal or from 2mg/400kcal.
<Desc/Clms Page number 10>
The concentrations of the following carotenoids are preferably: Beta-carotene: 0. 01 to 1. 5mg/400kcal, preferably 0.5 to 1mg/400kcal Lycopene: 0.01 to 1. 5mg/400kcal, preferably 0.5 to 1mg/400kcal Lutein: 0.05 to 1. 5mg/400kcal, preferably 0.5 to lmg/400kcal.
In particular, the present invention provides for a combination of carotenoids in the first aspect of the invention.
Preferred sources of the combined carotenoids include;
Red Palm Oil and Marigold Meal
Tomato Powder, Marigold Meal and Lucerne
Tomato Pomace and Marigold Meal.
As described above, the invention includes vitamin E and optionally other components. Useful combinations of the components (preferably in a canned or dry petfood) include ;
Vitamin E, vitamin C, taurine, red palm oil and marigold meal
Vitamin E, vitamin C, taurine, tomato powder, marigold meal and luceme
Vitamin E, vitamin C, taurine, tomato powder and marigold meal
Vitamin E, vitamin C, taurine, tomato powder and lucerne
Vitamin E, taurine, tomato pomace and marigold meal.
A combination of the present invention is;
Approx. active component mg/400kcaJ after production (Dry Product) Vitamin C 20mg ascorbic acid Vitamin E 50 IU Taurine 200mg (500 mg in wet product)
<Desc/Clms Page number 11>
Lutein 0. 17mg Lycopene 0.03mg Beta-carotene O. Olmg A further useful combination of the present invention is:
Vitamin E 50rU/400kcal Vitamin C 20mg/400kcal Taurine 500mg/400kcal Beta-carotene 0.5 to lmg/400kcal Lycopene 1 mg/400kcal Lutein 0-5 to 1mg/400kcal
Other useful components of the foodstuff according to the invention, include ; trace minerals (not direct antioxidants, but function as cofactors within antioxidant metalloenzyme systems), selenium (an essential part of the antioxidant selenoenzyme, glutathione peroxidase), copper, zinc and manganese (forming an integral part of the
antioxidant metalloenzymes Cu-Zn-superoxide dismutase and Mn-superoxide 'idant metalloenzymes I a dismutase.
In accordance with the method of the first aspect of the invention, the components may be administered, or consumed, simultaneously, separately, or sequentially.
In accordance with a second aspect of the invention, there is provided a dog or cat foodstuff which delivers to said animal, a concentration of ingredients sufficient to increase the antioxidant status of the animal.
<Desc/Clms Page number 12>
All preferred features of the first aspect of the invention also apply to the second. In particular all of the levels and preferred levels (including more preferred and most preferred levels) according to the first aspect also apply to the second.
Preferably, the dog or cat foodstuff provides an antioxidant status of greater than 20mg/l of vitamin E.
A third aspect of the invention provides a dog or cat foodstuff which provides a concentration of vitamin E at a level according to the first aspect of the invention. The concentration may be as stated according to the first aspect of the invention which
prov he particular ('nclud'n-preferred) provides the described percentage increases or the particular (including preferred) levels.
The dog or cat foodstuff according to the third aspect may also provide a concentration of vitamin C at a concentration also according to the vitamin C levels of the first aspect of the invention.
ZD'de, in addition, or as an The dog or cat foodstuff of the third aspect may provide, in addition, or as an alternative to the vitamin C, a concentration of taurine at a concentration also according to the taurine levels of the first aspect of the invention.
The dog or cat foodstuff according to the third aspect may provide, in addition to the vitamin C and/or the taurine or as an alternative, a concentration of a carotenoid at a concentration also according to the carotenoid levels of the first aspect of the invention.
Preferred features of aspects one and two, also apply to the third aspect.
<Desc/Clms Page number 13>
A fourth aspect of the invention provides a dog or cat foodstuff according to the third aspect of the invention, for use in the prevention or treatment of low antioxidant status in a dog or cat.
Preferred features of aspects one to three also apply to the fourth aspect.
A fifth aspect of the invention provides a dog or cat foodstuff according to the second, third, fourth or ninth aspects of the invention, for use in the prevention or treatment of any disorder which has a component of oxidative stress. The use is separately for the prevention or treatment of oxidative stress as a component of a"disease"or"disorder" (thus the disease or disorder may be reduced by alleviating (at least to an extent) a component of oxidative stress). Such disorders include; ageing, cancer, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure, neurodegenerative disease and immunity (such as compromised immunity).
Also included are prevention and treatment of oxidative stress caused by animal vaccinations (often annually) and anaesthetics, which may also be used for annual procedures such as dental treatments (which may require general anaesthetic) and exposure to UV light or radiation. With respect to immune function, this is equally applicable to those subjects who have a compromised immune function due to age (e. g. growing animals or senescing animals) as well as those experiencing immunological challenge. The maintenance of a healthy immune response (as well as optimising or boosting an immune response) in animals who are clinically healthy is also included in this definition.
The immune system of vertebrate animals is much discussed in the art (for example k "Immunology"by Roitt, Brostaff and Male, Gower Medical Publishing, London, New 9 to York, 1985). Immunological challenge includes infection, vaccination and other external factors such as anaesthesis (for example prior to surgery). It is an object of the present invention to provide a diet/foodstuff or supplement (and related aspects) which can be used to maintain, optimise or"boost"the immune system such that an
<Desc/Clms Page number 14>
improved immune response is given on an immunological challenge. An immune ZD response can be monitored by measuring antibodies produced in response to a given antigen. Such knowledge and technology is standard in the art. An improved immune response may be represented by a higher level (titre) of circulating antibodies within a given time frame, a faster detected antibody response or maintenance of the circulating antibody titre for a longer period of time.
An improved immune response assists the animal during an immunological challenge and can be particularly useful for young animals, since young animals may not have a fully developed immune system. As young animals are often vaccinated, the present invention provides means by which an improved immune response can be given by the animal when vaccinated. The present invention is particularly useful for feeding to a dog prior to vaccination with vaccine antigens for distemper, parvovirus and/or adenovirus. The present invention is particularly useful for feeding to a cat for vaccines or a combined vaccine against Feline Panleucopenia, Feline Calicivirus and/or Feline Herpesvirus. The length of time suitable for feeding prior to immune challenge depends on the animal in question and the immunological challenge. The foodstuff can be fed consistently. Periods of 8,6, 4,2 and 1 week prior to immune challenge are suitable. Longer periods are also suitable.
The present invention also provides a method (suitable for a dog or a cat) for preventing or treating a component of oxidative stress or a disorder which has a component of oxidative stress, said method comprising feeding said dog or cat a foodstuff according to the present invention. The disorders are as described above.
The invention also relates to a method for strengthening an immune response, in a dog or cat, to an immunological challenge, said method comprising feeding a foodstuff according to the present invention.
Preferred features of aspects one to four also apply to the fifth aspect.
<Desc/Clms Page number 15>
A sixth aspect provides for the use of vitamin E, in the manufacture of a medicament/clinical or veterinary diet for the prevention or treatment of any cat or dog disorder which has a component of oxidative stress, or for the prevention or treatment of oxidative stress.
Preferred features of aspects one to five also apply to the sixth.
A seventh aspect of the invention provides for the use of vitamin E at a level of 251U/400kcal or above, incorporated into a foodstuff as an is antioxidant, in a dog or a cat. All preferred features of aspects one to six also apply to the seventh. In particular, the levels of vitamin E may be as the preferred levels for vitamin E set out for the first aspect of the invention.
An eighth aspect of the invention provides a method for making a foodstuff according to any of the second to fifth aspects of the invention the method comprising mixing together at least two ingredients of the foodstuff. One of the components will be the required level of vitamin E. The preferred form of the foodstuff is a petfood product and therefore the method for making the petfood product, in any form, comprises mixing together the ingredients for the petfood product and incorporating one or more of the components according to the invention. The components may be added at any time during the manufacture/processing of the foodstuff, including at the end, as the last step before packaging.
The product can be made according to any method known in the art, such as in
1-y A Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chaptcr by A. Rainbird, entitled'A Balanced Diet", pages 57 to 74, Pergamon Press.
A ninth aspect of the invention provides a dog or cat foodstuff comprising vitamin C at a concentration of from 15mg/400kcal diet. The diet, foodstuff or supplement details are as those described for the previous aspects of the invention in relation to the
<Desc/Clms Page number 16>
vitamin C component to the extent that it comprises a vitamin C concentration of from 15 mg/400kcal diet. Features of aspects one to eight, as herein described may be individual or combined options together with the vitamin C concentration according to the ninth aspect of the invention. The ninth aspect of the invention provides a foodstuff useful for the prevention or treatment of a disorder which has a component of oxidative stress. Such disorders are also those as described above for the previous aspects of the invention. The inclusion of vitamin C in a dog or cat foodstuff is unique in as far as it relates to the concentrations of vitamin C stated and in particular or for the uses given.
The vitamin C concentrations range from 15mg/400kcal upwards. Preferred levels are those above 15mg/400kcal as set out above according to the preferred concentrations of vitamin C according to the first aspect of the invention. Because vitamin C is synthesised in vivo in both the domestic cat and the domestic dog it has never been of particular interest to consider introducing to a cat or dog supplemental levels of vitamin C via cat or dog food. However, the present invention shows that such a diet can be particularly useful, primarily for the production of a clinical diet/veterinary diet/medicament.
The present invention also provides for the use of vitamin C in a foodstuff for a dog or a cat. The use may be in the manufacture of a diet for the prevention or treatment of a disorder which has a component of oxidative stress or for the prevention or treatment of the oxidative stress component. Those disorders include cancer, ageing, heart disease, atherosclerosis arthritis, cataracts inflammatory bowl disease, renal disease, renal failure, neurodegenerative disease or compromised immunity, for example, an animal suffering from an infection. The present invention may also be used to treat or assist in the event of an immunological challenge in healthy animals.
The present invention also relates to a method for the prevention or treatment, in a dog 0 or cat, of a disorder which has a component of oxidative stress (or of the oxidative
<Desc/Clms Page number 17>
stress component) comprising feeding to said cat or dog a foodstuff according to the ninth aspect of the invention.
The following figures are referred to in the examples section:
Fig. 1, which shows an increase in vitamin E plasma status in dogs through supplementation with 50PU/400kcal and 10orU/400kcal of vitamin E.
Fig. 2, which shows vitamin C plasma status in cats, reflecting dietary vitamin
C supplementation.
Fig. 3, which shows vitamin E plasma status in cats with dietary vitamin E supplementation.
Figs. 4 and 5, which show levels of anti-parvovirus antibody titres with supplemented and unsupplemented diets, post vaccination.
Fig. 6, which shows an anti-distemper vaccine response with supplemented and unsupplemented diets, post vaccination.
Fig. 7, which shows maintenance of anti-adenovirus antibody titres in dogs supplemented with an antioxidant cocktail.
Fig. 8, which shows the measurement of FRAP in dogs fed an antioxidant diet for 8 weeks.
Fig. 9, which shows plasma vitamin E levels in dogs fed an antioxidant diet for
8 weeks.
<Desc/Clms Page number 18>
The invention will now be described with reference to the following non-limiting examples. Those skilled in the art will recognize that variations of the invention embodied in the examples can be made, especially in light of the teachings of the various references cited herein, the disclosures of which are incorporated by reference.
EXAMPLES Introductory Portion This section describes, firstly, how blood samples may be taken for determination of vitamin E, vitamin C, taurine and carotenoids. Also described are methods for analysis of components in plasma and methods for measuring components in food. In addition to the details set out below, details regarding analytical procedures can be found in McDowell L. R. (1989) Vitamin E: In Vitamins in Animal Nutrition Chapter 4, page 96, Academic Press, UK.
Plasma and Whole Blood Taurine Preparation of samples: Blood samples are collected into heparinarised bottles from either the cephalic or jugular vein. Following mixing of the sample on a roller, the samples are kept on ice for transfer to the laboratory. Whole blood is then frozen at-20 C until analysis.
Alternatively for plasma measurement, plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at OC). Plasma is frozen at -20oC until analysis.
The analysis of Taurine in cat plasma/blood is carried out by taking the sample and precipitating out protein by reaction with sulpho-salicylic acid solution. The sample is then centrifuged and the supernatant liquor filtered.
Reference-where plasma taurine has been measured in cats: Earle, K. E. and Smith, P. M. (1991) The effect of dietary taurine content on the plasma taurine concentration of the cat. British Journal of Nutrition 66,227-235.
<Desc/Clms Page number 19>
Plasma Vitamin C Preparation of samples: Blood samples are collected into hepannansed light-protected (foil-wrapped) bottles from either the cephalic or jugular vein. Following mixing of the sample on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at OOC). Plasma is frozen at -20oC until next-day analysis. Samples are prepared under subdued lighting at all times.
1 ml plasma extracted with 5ml extractant (I 5g metaphosphoric acid + 0. 475g EDTA + 20ml glacial acetic acid in 500ml water)-the procedure is then the same as for product.
A preferred minimal dose of vitamin C to achieve an increase in plasma in cats is 20mg/400kcal. A preferred minimal dose of vitamin C tested to achieve an increase in plasma in dogs was 27mg/400kcal.
Plasma Vitamin E Preparation of samples: Blood samples are collected into heparinarised bottles from either the cephalic or jugular vein. Following mixing of the samples on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at OOC). Plasma is frozen at-20 C until analysis.
Sample size = 250nul. The sample is extracted into hexane after the addition of tocopherol acetate as internal standard. The hexane is evaporated and the residue dissolved in methanol and injected onto the HPLC. Separation is achieved using a reverse-phase column with methanol as eluent with UV detection at 285nm.
<Desc/Clms Page number 20>
A preferred minimal dose of vitamin E to achieve an increase in plasma in cats is 34 1U/400kcaL A preferred minimal dose of vitamin E tested to achieve an increase in
plasma in dogs was 50IU/400kca1.
0 Carotenoid determination in plasma Blood samples are collected into heparinarised light-protected (foil-wrapped) bottles from either the cephalic or jugular vein. Following mixing of the samples on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at OOC). Plasma is frozen at-80 C until analysis. Samples are prepared under subdued lighting at all times.
The following two methods may be used to determine carotenoid concentration in plasma.
Method I The first method is to measure the major carotenoids of interest, with the exception of lutein and zeaxanthin which will not be separated using this method.
The method used to detect carotenoids is a variation of that of Craft, N. E. and Wise, S. A., Journal of Chromatography, 589, 171-176, (1992).
The extraction of carotenoids from plasma is achieved using a variation of that of Thumham et. al. Clinical Chemistry, 34,377-381, 1988.
Method 2 The second method is to separate lutein and zeaxanthin and to separate the different isofonns of the carotenoids.
The method used to detect the carotenoids is a variation of that ofYeum, Kyung-Jin., et. al. Am. J. Clin. Nutr, 64, 594-602, 1996.
<Desc/Clms Page number 21>
The extraction of carotenoids from plasma is achieved using a variation of that of Thumham et. al. Clinical Chemistry, 34, 377-381, 1988.
All extractions were carried out under subdued lighting, and all stock solutions of carotenoids were stored under argon.
Vitamin C-Food Product Ascorbic acid is enzymatically oxidised to dehydro ascorbic acid which is condensed with o-phenylene diamine to the fluorescent quinoxaline derivative. The latter is separated from interfering compounds by reversed-phase HPLC with t1uorimetric detection.
Vitamins A & E Food Product The sample is hydrolyse with ethanolic potassium hydroxide solution and the vitamins extracted into petroleum ether. The petroleum ether is removed by evaporation and the residue is dissolved in propanol The concentration of vitamin A and E in the propan-2-ol extract is determined by reversed-phase liquid chromatography.
Free Taurine-Food Product Free Taurine is that which is nutritionally available in a product.
The analysis of Free Taurine is carried out by taking the sample, adding dilute Hydrochloric acid. This is then macerated and transferred to a volumetric flask. A small amount is then taken and sulpho-salicylic acid is added to precipitate the protein. The sample is then centrifuged and the supernatant liquor filtered. The resulting
solution is reacted with dansyl chloride and analysed by HPLC using fluorescence I detection.
<Desc/Clms Page number 22>
Carotenoids-Food Product I ium 20-25g sample taken for analysis. Sample is saponified with 28% ethanolic potassium hydroxide for 30mins. At 900C under nitrogen and with pyrogallol as antioxidant.
After cooling, the saponifie extract is extracted with 2x250ml mixed ethers (pet. Ether/diethyl ether 1 : 1) and the organic phase is washed with water until neutral. The ether extract is evaporated at 35 C under vacuum with BHT as antioxidant and the residue redissolved in the HPLC mobile phase. The carotenoids are determined using
reverse phase HPLC using UV detection at 450nm.
I In addition to the experimental work given, the invention was an indicator of improved health by decreasing the osmotic fragility of cat erythrocytes following feeding of the antioxidant cocktail to cats.
The ability of red blood cells (erythocytes) to withstand osmotic stress was tested.
The method involved re-suspension of washed erythrocytes in solutions with different NaCl concentrations; these are incubated and then centrifuged. Haemoglobin is released from the cells according to their osmotic fragility. Results showed that erythocytes of cats fed antioxidant cocktails of the invention showed a greater resistance against osmotic stress as significant lower concentrations of NaCl were required to induce the same level ofheamolysis. The ability of erythocytes to tolerate
situations of osmotic stress is an indicator of an improved physiological status.
Example 1 Vitamin E A group of 8 dogs were maintained a nutritionally complete diet (see reference section representative diet) for a period of 6 weeks prior to receiving one of the two supplementary levels of vitamin E (alpha-tocopherol acetate below (table 1)).
<Desc/Clms Page number 23>
Table 1 : Vitamin E content in test diet before supplementation
Diet Vitamin E content before Supplementation Complete and balanced 8.7 IU/400kcal Plasma levels significantly (p < 0. 05) increased following only I week of supplementation at both the 50IU/400kcal and IOOIU/400 kcal level.
Plasma saturation appeared to occur after I week of supplementation. Plasma levels
declined to baseline levels after 2 weeks of stopping supplementation.
0 It can be concluded from the doses studied, that dietary supplementation with vitamin E significantly increases plasma status in dogs by a magnitude of 60-66% (figure 1).
Example 2 Antioxidant Supplementation in Cats Vitamin C 4 groups of 8 or 9 cats were given oral supplements of vitamin C at 4 different levels whilst being maintained on a nutritionally complete diet (see reference diet section).
Baseline plasma vitamins C levels demonstrate that there are no significant differences between the groups prior to supplementation.
As can be seen in figure 2, within 7 days the plasma vitamin C levels for all 4 groups significantly increased above their baseline prior to supplementation.
Although the higher vitamin C supplements resulted in greater plasma values, the increase was not significantly different between the 4 groups.
<Desc/Clms Page number 24>
Following the end of the supplementation period plasma vitamin C levels returned to baseline.
These data demonstrate that the antioxidant status of cats can be increased with vitamin C supplementation of their diet at relatively low levels.
Example 3 Vitamin E The impact of typical dietary vitamin E levels on the vitamin E status of cats has been evaluated, as well as the effect of dietary supplementation.
The plasma vitamin E concentrations of 2 groups of 12 cats maintained on 2 I groups of 12 cats maintained on 2 commercial nutritionally complete cats diets (see reference diet section) with different dietary vitamin E levels were determined. The plasma levels (duplicate measurements 2 weeks apart) seen in Table 2 demonstrate that cats maintained on a diet for a period of 4 weeks with a higher vitamin E level have a relatively increased vitamin E status.
Table 2: Vitamin E plasma status in cats reflecting vitamin E intake
Vitamin E content Plasma Vitamin E (SD) ug/ml 60IU/400kcal 26. 627. 2 241U/400kcal 15. 094. 0 In order to determine the effect of supplementation, oral vitamin E supplements (a-
tocopherol acetate) were administered to a group of 12 cats whilst being maintained on I I the nutritionally complete diet.
The effect of the supplementation can be seen in figure 3. Plasma vitamin E levels
<Desc/Clms Page number 25>
were significantly increased following supplementation, reaching saturation after approximately 4 to 6 weeks of supplementation.
Hence, dietary vitamin E supplementation can enhance the antioxidant status of cats.
Example 4 Total plasma antioxidants in cats ; normal ranges and influence of age.
The total antioxidant status in the domestic cat has never previously been reported.
The aim of this study was to validate a method of determining total antioxidant status in the cat, determine normal total antioxidant ranges in healthy adult cats and investigate the effect of age on total plasma antioxidant status.
A colorimetric assay kit (NX2332) manufactured by Randox Laboratories Limited, was validated for the determination of total antioxidant status in the cat. Assay precision was determined both by replicate analysis of cat plasma samples, and of commercial quality control (QC) material (PAR 721013 and PAR 721014; Bio-stat Diagnostics), Intra and Inter assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays with plasma sample CV < 10%, and QC CV < 5%. Dilution of cat plasma produced a linear response in the assay.
The effect of ageing on plasma antioxidant levels was evaluated. 134 cats, maintained on a range of nutritionally complete cat foods (see diet reference section), participated in the study. Total antioxidant status was evaluated in single plasma samples from 69 male and 65 female domestic shorthaired cats aged between 6 months and 14 years.
All means are quoted the standard deviation (SD).
The results indicate the presence of a transitional period of antioxidant status occurring
at approximately 6 years of age. A Newman-Keu1s multiple range test showed that the z : l
<Desc/Clms Page number 26>
total plasma antioxidant status of cats aged under 6 years was significantly (p < 0. 01) higher than those aged over 6.5 years (see Table 3). It is not known whether a decline
in anrioxidant status at this age signals a greater susceptibility to illness or whether in ant oxi 1-1 antioxidant status in this age influences lifespan in cats. ntioxi I Ia Table 3. Mean total plasma antioxidant concentrations from cats categorised according to age.
Age Category (years) Total Plasma Antioxidant Number of Status (mmol/l) + SD animals < 6 0. 9200. 77' 47 6 0. 8720. 182 ab 9 > 6 0. 7990. 092'''78
jMp < ? cypf agMC'fe o/Mogec'M. s' g/'OM Example 5 Total plasma antioxidant and superoxide dismutase status in dogs Little is known about the antioxidant status in the domestic dog. The aim of this study was to validate a method of, and determine normal ranges of, total plasma antioxidants (TPAO) and erythrocyte SOD (superoxide Dismutase) activity in the dog.
Colorimetric assay kits manufactured by Randox laboratories Limited were validated for determination of TPAO status (Kit No : NX2332 and SOD status (Kit No: SD 125 in the dog. For TPAO, assay precision was determined both by replicate analysis of dog plasma samples, and, of commercial quality control (QC) material (PAR 721013 and PAR 721014 : biostat Diagnostics) - Inter and Intra assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays, with plasma sample CV < 10% and QC < 5%. SOD status assay precision was determined by
<Desc/Clms Page number 27>
replicate analysis of dog erythrocyte samples. Inter and Intra assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays with erythrocyte sample CV < 10%.
TPAO and erythrocyte SOD status were evaluated in 30 male and 20 female dogs aged between 9 months and-16 years. Ten breeds were represented. All dogs were clinically normal, and had been maintained long-term on a variety of manufactured nutritionally complete diets. There was no apparent relationship between age and TPAO or SOD activity. Dogs were not equally represented across the age groups (data not shown), and further work is in progress to assess whether this observation is supported by a larger sample size and better age spread. No significant difference was seen between the gender for either mean TPAO status (male : 0. 7190. 135, female: 0. 786~0.101) or SOD activity (male: 1275.41 +264. 46, female : 1267. 61 : t166. 34 U/g
Hb). However, Bartletts Test showed a significant difference (p < 0. 05) between variance of SOD activity in male (6994. 0) and female (27670. 3) dogs. Analysis of those breeds with five or more representatives showed a significant difference (pO. Ol) for both SOD activity, and TPAO status, between breed but not gender. Newman-Keuls multiple range tests showed Beagles to have significantly lower mean SOD activity (p < 0. 05) and mean TPAO status p < 0. 01) than Labradors and Yorkshire Terriers, Table 4.
Table 4. Superoxide dimutase and total plasma antioxidant activity for three breeds of dog.
Breed Mean SOD activity SD Mean TPAO n activity SD Beagle 1084. 70~136.24a 0.569~0.094a 10 Labrador 1323. 65i185. 77' 0. 8300. 113b 15 t
<Desc/Clms Page number 28>
Yorkshire Terrier 1293. 76i215. 54'" 0. 7980. 036'' 5
Superscripts denote homogeneous groups within columns (Newman-Keuls multiple range test) n=number of animals These data indicate that it may not be sufficient to assume a single value for normal SOD and TPAO ranges in dogs-In this instance two values are required, one for Beagles and one for the other two breeds. The 95% confidence intervals for the mean ranges of TPAO status and erythocyte SOD activity in Beagles are 0.569 0. 067 mmol/l and 1084.9 97. 27 U/g Hb respectively, and for the other two breeds; 0. 822 : t 0.047 mmol/l and 1316.2 88. 03 U/g Hb.
Example 6 Assessment of total antioxidant status in the cat and dog using a fully automated color-metric assay The aim of this study was to validate a colormetric assay kit, manufactured by Randox
Laboratories Ltd, for the determination of total antioxidant status in the cat and dog.
I Secondly the validated assay was used to assess changes in total antioxidant status of the cat and dog with age and to compare these changes in other biochemical and 9 1- haematological parameters. The assay reacts 2, 2'-Azino-di- (3-ethylbenzthiazoline sulphonate) (ABTS) with a peroxide and H202 to produce a radical cation ABTS+ which can be measured to 600nm. Antioxidants present in a sample will cause suppression of this colour production to a degree proportional to their concentration.
The assay was performed on a Cobas Mira analyser (Roche Diagnostics) using the protocol supplied by Randox Laboratories. Assay precision was determined by replicate analysis of cat and dog plasma samples and of commercial quality control (QC) material Inter-assay and intra-assay CV were both less than 5% for the QC material and were both less than 10% for the cat and dog plasma samples. Dilutions
<Desc/Clms Page number 29>
of cat and dog plasma produced a linear response in the assay. Routine haematology and biochemistry profiles, including total antioxidant status, were performed on domestic short haired cat and on several breeds of pedigree dogs of various ages. Antioxidant status in the cat increased up to 2 months of age, but then showed a subsequent decline. No sex difference were apparent. Female dogs of less than 1 year showed a slight decrease in antioxidant status, otherwise there was no significant change with age. Multiple regression analysis demonstrated a relationship between antioxidant status, albumin, asparate aminotransferase and calcium in the cat and antioxidant status, phosphate and alanime aminotransferase in the dog. The validation results were considered to be acceptable and the assay is suitable for the determination of total antioxidant status in the cat or dog.
Example 7 Effect of a vitamin C supplement on plasma status in healthy adult cats.
Vitamin C is a major water soluble antioxidant ill vivo, that can delay or inhibit oxidation, important particularly in extracellular fluids. However the response in the cat (Felis domesticus) to different dietary levels of vitamin C has not been previously investigated. The aim of this study was to establish the effect of vitamin C supplementation in healthy adult cats on plasma status.
Plasma vitamin C concentrations of 33 cats were determined by reversed-phase High Performance Liquid Chromatography. Subsequently the cats were allocated into 4 groups by stratified randomed sampling, ensuring there were no significant differences between the baseline plasma vitamin C levels of the 4 groups (ANOVA p > 0. 05).
Daily vitamin C supplements (crystalline L-ascorbic acid, ICN Pharmaceuticals, UK, in a gelatine capsule, Analytical Supplies Limited, UK) were given orally to the cats for 21 days. The 4 groups of cats received either 3.5, 7.0, 10.5 or 21.0 mg vitamin C/day. Plasma vitamin C levels were determined at 7,14 and 21 days of supplementation, as well as, at 21 days post-supplementation. All cats were
<Desc/Clms Page number 30>
maintained on a nutritionally complete canned diet, with a vitamin C content of 11.6 mg/l. 6MJ.
The plasma vitamin C levels of the cats significantly increased at 7 days after daily supplementation at all 4 dietary levels administered (paired t-test p < 0. 05), and during the supplementation period these levels were maintained, Table 5. Although the higher dietary supplementation levels of vitamin C achieved greater plasma values when compared with those of the lower dietary levels, there were no significant differences between dietary groups in the plasma increases (repeated measures multifactor ANOVA using General Linear Model p < 0. 05). The plasma levels of all cats returned to baseline levels 21 days post-supplementation.
Table 5. Plasma Vitamin C Concentrations (ug/ml SD)
Group n Time of supplementation (days) 21 days 0 7 14 21 postsupplementation 1 8 3. 93'0. 98 4. 73b0.71 4.73b~0. 39 5. 020. 64 3. 66'0. 74 2 8 4. 16'1. 18 5. 28'0. 99 5. 55b : t0. 67 5. 200. 82 4. 17'0. 73 3 8 4. 34a~1.24 5.20a~1.16 5.46b~1. 02 5. 42b~1.28 4.56a~1.14 4 9 4.41a~0.96 5.91b~1.04 5.90b~0.54 5.85b~0.80 4.17a~0.65 Heterogeneous superscripts within rows indicate a significant difference with time (ANOVA p < 0. 05) These data demonstrate that at low levels of dietary supplementation with vitamin C administered on a daily basis, the plasma status of cats can be significantly enhanced.
Continual supplementation is required in order to maintain the enhanced plasma status.
Example 8 Validation and normal ranges of plasma ceruloplasmin concentration in cats and dogs.
<Desc/Clms Page number 31>
The cuproenzyme, ceruloplasmin has a number of functional roles with the body. As a copper storage protein, ceruloplasmin helps protect against the catalytic ability of free copper ions. Free copper can accelerate autoxidation reactions through single-electron (radical) transfer, as well as react with hydrogen peroxide to form highly reactive hydroxyl radicals which can lead to cellular disruption. At time of trauma, ceruloplasmin also promotes the conversion of iron from its pro-oxidant ferrous form to ferric iron. As an acute phase protein, ceruloplasmin can be indicative of inflammation or infection and thus be used in conjunction with serum ferritin as a measure of iron stores.
A colorimetric method to determine ceruloplasmin oxidase activity in cats and dogs was validated based on the method of Sundennan F. W. and Nomoto, S. (1990) Clin.
Chem 16, 903 using p-phenylenediamine as the substrate. Two dog and two cat serum samples were analysed ten times within a single run. Intra-assay coefficient of variation of 1.94% and 2.95% were determined for the dog samples, and 1. 81% and 3.94% for the cat. Analysing the same samples on ten separate days, inter-assay coefficients of variation of 8. 21% and 7. 01% for dog, 6.88% and 9.35% for cat samples were determined. Hence an acceptable level of intra-and inter-assay variability was achieved. Following this, the difference between the ceruloplasmin concentration of serum and plasma samples was evaluated. No significant difference was determined between plasma and serum samples for either species Hence thereafter plasma samples were collected in order to reduce the total volume of sample required.
In order to establish normal ranges, plasma samples were obtained from 102 healthy dogs (mixed breed, age and sex) and 54 healthy domestic short-haired cats (mixed age and sex). The mean plasma ceruloplasmin concentrations determined for dog and cat where 9.28 IU/L (SD 3.03 IU/L) and 10. 90 IU/L (SD 3.34 IU/L) respectively. Using
these values, normal ranges (mean 2SD) of 3. 22 IU/L 15. 35 IU/L for dogs, and 4. 22 0
<Desc/Clms Page number 32>
IU/L to 17. 58IU/L for cats were established. This nonnal range detennined for dogs is 9 consistent with that previously reported (Solter P. F, et al (1991) Am J Vet Res 52, 1738,1991) A normal range for cats has not been previously established, however its similarity to that of the dog suggests that there is little difference in circulating ceruloplasmin levels between these two species. The normal ranges established during this study may be used to evaluate the health status of cats and dogs.
Example 9 Canine ferritin : Assay validation and normal range for serum.
Ferritin plays an important role in the antioxidant defence system with the body. As a
high affinity storage protein for iron, ferritin maintains iron in a safely bound form m I I I I I preventing the reactive ferrous ion from participating in Fenton reactions, which can lead to oxidative damage. In normal health ferritin, a species-specific protein, if found in the blood at concentrations that reflect body iron stores and in conjunctions with other parameters can be used to assess in vivo iron status. In order to determine circulating fenritin levels in the dog, an enzyme-linked immunoassay (ELISA) was developed, adapted from the method of Weeks, B. R. et al (1988) Am J Vet Res 49, 1193) (1988) using monoclonal antibodies. Following the assay validation, a normal range for dogs was established.
In the range of 0-40 ng/ml the ferritin standards were linear (least squares regression analysis, r=0. 997) and the recovery of purified ferritin added to canine sera was 97.7%. The intra-assay coefficient of variations derived from determining the ferritin concentration in two serum samples 12 time were 8.2% and 6. 6%. The inter-assay coefficient of variations of two serum samples assayed 10 time on separate days were 16.6% and 16. 2%.
Serum samples were obtained from 96 healthy dogs of mixed sex and five different
<Desc/Clms Page number 33>
breeds for ferritin determination in order to establish a normal range. Each sample was assayed either in triplicate or quadruplicate and the mean of these values was used as the ferritin concentration for that sample. The serum ferritin concentrations varied from 67.20 to 621.07 with a mean value of 371. 62 ng/ml (SD 102.85 ng/m1). The data was normally distributed. These results demonstrate that serum ferritin can be determined with good repeatability and reproducibility for dogs. The values obtained will be used as a normal range for future studies and may provide a useful method of determining iron storage levels in dogs.
Example 10 Supplementation of dietary tocopherol increases canine plasma values outside the normal ranges Vitamin E is the collective name for 8 naturally occurring molecules, 4 tocopherols and 4 tocotrienols. The biological activity of the various forms roughly correlates with their antioxidant activities with the order of relative peroxyl scavenging reactivities of a > p > y > 5-tocopherol. Generally it is accepted that providing nutrients in excess of the requirement does not deliver any measurable benefit. The minimum requirement for vitamin E in adult dogs has been established as 2.5 IU a-tocopherol/400kcal diet (Nutrient Requirements of Dogs (1985) National Research Council (U. S. ) National Academy Press Washington DC ISBN: 0-309-03496-5). Prepared petfoods typically contain up to 10 times this amount but across the normal ranges of vitamin E in petfoods, plasma concentrations tend to be constant. In a study to evaluate the impact of supplementary vitamin E on the plasma response, 6 adult dogs, maintained on a nutritionally complete (see diet reference section) canned dog food (vitamin E content 8.2 mg/400kcal (8. 2IU/400kcal), were offered a supplement equivalent to 100 IU vitamin E/day for 6 weeks. A control group of 6 dogs was maintained under the same conditions-but received no dietary supplement. Plasma a-tocopherol was monitored during, and for 4 weeks following, the supplementation period.
<Desc/Clms Page number 34>
The plasma a-tocopherol levels are presented in Table 6. The treatment group had a mean baseline plasma ex-tocopherol level which was not significantly different from the control group (p=0-43). Following 2 weeks of supplementation the mean value of the treatment group had significantly increased compared to the control (p=0. 002) and the baseline value (p < 0. 001). Measurements made on days 56 and 70 (days 14 and 28 post-supplementation) showed levels which remained significantly higher than baseline. These results clearly indicate that dietary vitamin E above the levels typically found in prepared petfoods can elevate plasma status in dogs and that this can be sustained for several weeks following supplementation. In order to saturate plasma it appears that levels greater than those currently found in prepared petfoods may need to be fed. Given the potent antioxidant capacity of vitamin E it may prudent to increase vitamin E status in dogs, in order to maximise the opportunity to prevent freeradical damage and the associated degenerative disease.
Table 6. Plasma response to a-tocopherol supplementation in healthy dogs
* represents homogeneity (p > 0. 05) within the same group
. represents homogeneity (p > 0. 05) between the 2 groups Example 11 Typical plasma vitamin E ranges in healthy dogs Vitamin E is a collective name for eight different tocopherols and tocotrienols which share the'same biological activity. Of the eight, a-tocopherol is biologically and chemically the most active form of vitamin E and 1mg a-tocopherol is equivalent to
<Desc/Clms Page number 35>
lID of vitamin E. Vitamin E is a potent antioxidant in the body, and it primarily resides in biological membranes where it protects membrane phospholipids from peroxidation damage. Vitamin E also inhibits oxidation of vitamin A and therefore also protects against vitamin A deficiency. The minimum requirement for vitamin E in adult dogs has been established as 2.5 ill a-tocopherol/400kcal diet (Nutrient Requirements of Dogs (1985) National Research Council (U. S. ) National Academy Press Washington DC ISBN : 0-309-03496-5). However, there is a paucity of information as to normal vitamin E plasma values in healthy adult dogs and puppies.
In order to determine typical baseline plasma a-tocopherol levels in healthy adult and pi puppy dogs, a series of studies were carried out in dogs fed a range of canned and dry nutritionally complete prepared petfoods (see diet reference section), Table 7. Diet was fed in accordance to body weight (110 kcallkgO 75). The individual plasma a- tocopherol levels ranged from 9 to 39.2 mg/l with a median value of 21. 1 mg/1. There were no significant differences between the mean baseline a-tocopherol levels of the groups of dogs maintained on the different diets (p=0. 24). These data indicate that typical a-tocopherol levels in puppies and adult dogs are similar and that, within the usual vitamin E levels found in prepared petfoods, plasma tocopherol levels exhibit similar ranges.
Table 7. Diet a-tocopherol level (IU/400kcal) is shown with the corresponding means plasma a-tocopherol level (mg/lSD).
Food format a-Tocopherol Plasma a-n content Tocopherol (TIJ/400kcal) (mg/ISD) Canned 9.77 21. 156. 4 20 Dry 6.31 22.72~6.62 6 Dry 13-76 25. 335. 12 10
<Desc/Clms Page number 36>
Dry 18 21.56~4.88 23 Example 12 Exercise in healthy adult dogs increases plasma TBARS-an indicator of oxidative stress.
Plasma TBARS (thiobarbituric acid reactive substances) measured by HPLC with precolumn derivatisation is a well-documented maker of lipid peroxidation in vivo. The
aim of this present study was to survey the effects of a bout of exercise in dogs (Canis 1 0 familiars) upon this index of oxidative stress.
A panel of 14 dogs of mixed breed and age were maintained on a nutritionally complete commercial dry diet or three months prior to, and throughout the duration of this trial. The extent of lipid peroxidatation immediately prior to an following an acute 20 minute bout of paddock exercise was quantified by determining the malonaldehyde (MDA) formed as TBARS. This analysis was measured according to the method described by Bird, R. P. & Draper, H. H. (1984), Methods in Enzymology.
105: 299-305 (1984). The results revealed a significant increase (22%) in plasma
TBARS (Paired TTest p < 0. 05) following exercise (0. 74 M 0. 2 pre-, 0. 92 uM 0. 2 post exercise). In order to audit for increases occurring as a direct result of concentrated blood volumes post-exercise, PCV (packed cell volumes) and plasma albumin were measured. Results did not reveal a significant difference pre-and postexercise (p > 0.05) and therefore the observations from this study suggest that augmented lipid peroxidation in vivo occurs as a direct result of exercise-induced oxidative stress. Literature proposes that the specific site of oxidative damage is the cellular membrane, where peroxyl radicals (R02) proliferate in conditions of high oxidative stress. This observation infers a potential role for dietary lipid-phase antioxidant intervention in healthy adult dogs.
Other examples of the antioxidative status of animals and the effects of the inventive
<Desc/Clms Page number 37>
antioxidant cocktail on animals are described below.
Example 13 Dietary Carotenoid Absorption in the Domestic Cat.
It is found that antioxidants, such as beta-carotene and lycopene, incorporated into commercial cat food will result in a significant increase in the absorption of carotenoids in cats, despite their metabolic carnivorous adaptation. In this study three canned cat diets were manufactured using the same batch of raw ingredients with an identical base recipe. The control diet, Diet A, had a metabolisable energy (ME)
content of 3. 39 MJ/kg with a beta-carotene and lycopene content of > 0. 1 mg/1. 67 MJ ME. Diet B was supplemented with red palm oil (3. 70 MJ ME/kg) with a betacarotene content of 0. 36 mg/1. 67 MJ ME, and a lycopene content of > 0. 1 MG/1. 67 MJ ME and Diet C was supplemented with tomato pumice (3.54 MJ ME/kg) with a betacarotene content of > 0. 1 MG/1. 67 MJ ME and a lycopene content of 0.9 MG/1. 67 MJ ME.
Two groups of five healthy cats each were selected for the study. The cats of Group 1 had a mean age of 8.72 years (SD2.1 years) and included 3 males and 2 females. The Group 2 cats had a mean age of 7.4 years (SD 1.7 years) and included 2 males and 3 females. All of the study cats were previously maintained on a variety of commercial, nutritionally complete, prepared cat food and then were maintained on Diet A for a period of seven days to allow acclamation to the diet. On day eight of the study, a baseline plasma carotenoid level was determined. Subsequently, Group I cats were fed Diet B and Group 2 cats were fed Diet C, for a period of five days. On day 13 of the study, a plasma sampling was repeated in the same manner as for the baseline samples. The analyses were carried out by High Performance Liquid Chromatography.
The beta-carotene concentration of the Group 1 cats on Diet B, increased significantly
<Desc/Clms Page number 38>
(mean 17. 62 ng/mL, SD 2. 50 ng/mL) above the baseline values (mean 6. 35 ng/mL. SD 3. 23 ng/mL). In this group, the plasma lycopene concentrations remained below the 1 1 limit of detection. In the Group 2 cats, on Diet C, there was no significant change in the plasma beta-carotene concentrations of the baseline levels (mean 5. 30 ng/mL, SD 5.78 ng/mL) and the post-feeding levels (mean 6. 61 ng/mL, SD 2.83ng/mL).
However, Group 2 cats showed a significant increase in plasma lycopene concentrations from a baseline level of 0 ng/mL to a post-feeding level of mean 14.6 ng/mL, SD 7.25 ng/mL.
Thus, this study demonstrates that natural sources of antioxidants, such as betacarotene and lycopene, incorporated into commercial cat food will result in a significant increase in the absorption of carotenoids in cats, despite the metabolic carnivorous adaption. This increase in circulating antioxidants will provide a beneficial effect to the antioxidative status of cats. This increased absorption of carotenoids in cats has not heretofore been seen at such low dietary concentrations.
Example 14 Maternal milk may be insufficient to promote a maximal antioxidant status in the developing kitten.
With respect to immune function, the effect of antioxidants is equally applicable to animals who have a compromised immune function due to age, e. g. growing animals, as well as those experiencing immunological challenges. The results of the following study show that maternal milk may be insufficient to promote a maximal antioxidant status in the developing kitten, which in turn may contribute to the increased susceptibility of kittens to oxidative stress. Thus, it can be found that the administration of an antioxidant cocktail as a dietary supplement for kittens will likewise show an improvement in antibody response time as is found in puppies receiving the antioxidant cocktail supplement.
<Desc/Clms Page number 39>
The ability of mammals to resist oxidative insult depends on both their endogenous antioxidant defense systems and the contribution to overall antioxidant status provided by diet. One way to measure an animal's antioxidant status is to evaluate its total plasma antioxidant capacity (TPAO). A colormetric assay kit manufactured by Randox Laboratories Ltd. has been validated for use in cats to assay the normal range of TPAO. Antioxidants present in blood samples will cause suppression of the color production in the assay proportional to their blood concentration.
This study was conducted to determine the normal range of TPAO in healthy kittens and to determine whether there is any relationship between age and TPAO. Plasma samples were obtained from 16 health kittens (8 males, 8 females) at 14,35 and 60 days of age. The samples were assayed using the method as described above and the results were compared using ANOVA. The results are illustrated in table 7 below: Table 7.
Age of Kittens TPAO 14 days 0.694 : t 0. 069 35 days 0. 853 : t 0.083 60 days 1. 030O. U3 From the results, it can be seen that the TPAO status of suckling kittens is at the bottom end of the normal adult range, only achieving adult levels between 35 and 60 days. At 14 days after birth, kittens are completely dependent upon maternal milk to provide their nutritional requirements. At 35 days of age the kittens are far less dependent on maternal milk and obtain the majority of their nutritional intake from sold foods, while at 60 days they are fully weaned. These results suggest that maternal milk is insufficient to promote maximal antioxidant status in the developing kitten, which in turn contributes to the increased susceptibility of kittens to oxidative stress.
<Desc/Clms Page number 40>
Example 15 The antioxidant fortified diet increases the antioxidant capacity of cats.
A group of 46 healthy domestic short haired cats were randomly stratified into 2 groups of 23 cats dependent upon age and sex. Group A were maintained on a control base diet (a complete wet diet according to the reference section) and Group B on a wet diet supplemented with an antioxidant cocktail for a period of 30 weeks.
The cocktail was:
Vitamin E 50IU/400kcal diet Vitamin C 20mg/400kcal diet Beta-carotene 0. 5-l mg/400kcal diet Lutein 0.5mg/400kcal diet Taurine 200mg/400kcal diet Lycopene Img/400mg kcal diet Fasting samples were obtained from all cats and assessed for antioxidant capacity using the ferric reducing antioxidant power (FRAP) and the ferric reducing antioxidant power and ascorbic acid concentration (FRASC) assays.
The antioxidant capacity was significantly increased (p < 0. 05) in Group B compared to Group A with respect to both FRAP and FRASC.
GROUP MEAN FRAP SD MEAN FRASC SD A 260.45 : t 55. 59 28. 05i7. 93 B 297. 63i57. 18 36. 33i10. 69 Hence, the antioxidant capacity was increased in cats fed the antioxidant fortified diet, which confers an increased ability to mitigate the deleterious effects associated with oxidative insult.
<Desc/Clms Page number 41>
Example 16 Influence of the antioxidant supplemented diet on the immunological status of cats EXPERIMENTAL DESIGN : 48 normal healthy cats were fed a control diet (complete diet as per the reference section) for six weeks after which baseline measurements were taken. Cats were then allocated to either control or treatment age-matched groups and fed the supplemented diet described in Example 15. At week eight the animals were sampled in order to determine serum immunoglobulin concentrations. At week twelve immune parameters were measured and the cats were immunised (using a standard combined vaccine against Feline Panleucopenia, Feline Calicivirus and Feline Herpesvirus). At week eighteen final measurements were made post immunisation.
METHODS USED :-
Assessment of peripheral blood mononuclear cellular (PBMCM proliferative response by mitogen induced lymphocyte transformation assay (MILT) Peripheral blood mononuclear cells were isolated from hepannised blood by density gradient centrifugation on Histopaque 1077 (Sigma). The cells were washed twice with phosphate buffered saline (PBS) and once with RPMI-1640 (Dutch modification) supplemented with 10 per cent heat inactivated fetal calf serum, 1 per cent penicillin/streptomycin and 2 per cent sodium pyruvate. Cell viability was assessed by the trypan blue exclusion test (Sigma).
Cells were cultured in triplicate at 1 x 105 per well in 96 well flat bottomed microtitre plates at 37oC, with phytohaemagglutinin (PHA) (5 g/ml) (Murex), concanavalin A (Con A) (7.5 g/ml) and pokeweed mitogen (PWM) (I j. lg/ml) (Sigma) for 96 hrs.
<Desc/Clms Page number 42>
Proliferation was measured by H]-thymidine incorporation in counts per minute (CPM) (0. 5 Ci/well) during the final 18 hrs of culture.
Analysis of lymphocyte subsets bv flow cvtometry CD4 and CD8 positive cells are the most well characterised lymphocyte subsets in feline immunology and an adequate repertoire of these cells is indicative of a healthy immune system. The assay was performed using both purified lymphocytes and whole blood and a selection of various monoclonal antibodies (Mabs).
RESULTS
ksessment of PBMC proliferative response by mitogen Induced lymphocyte transformation assay (MILT) Table 8 shows the response of PBMC to the mitogens PHA, Con A and PWM prior to and post immune challenge Mitogen induced lymphocyte transformation assay (MILT) data showed no significant changes in proliferative response for either control or treatment groups. When an analysis of stimulation indices was undertaken there was a significant decrease in the treatment group in both the PHA stimulation index (S I) (p < 0.05) and the Con A index (p < 0. 00l) from pre to post-immunisation There was no significant difference in the SI of the control group. The Pokeweed 51 increased
significantly from baseline to pre-immunisation in both groups (p < 0. 05) and decreased I I rii 1 1 significantly in the treatment group post immunisation (p < 0. 01).
Table 8.
<Desc/Clms Page number 43>
The response of PBMC to the mitogens PHA, Con A and PWM prior to and post immune challenge.
[3H]thyrmidine incorporation (counts per mtn) CPM x 10'' MEAN SEM Stimulation index (S. I.) MEAN ~ SEM Pre-PostBaseline immunisation immunisation standard lara plus b standard lara plus standard lara plus (n =22) (n = 23) (n =22) (n = 23) (n =22) (n = 23) Unstimulated 20 ~ 4 21.6 ~ 4 27.2 ~ 3.6 18.2 ~3 30.9 ~ 3. 9 252. 6 PHA 38. 8 ~4 41.5 ~ 6 33.7 ~ 3.9 28.5 ~ 3.2 38.8 ~ 4 33.3 ~ 3 S. 2. 01 ~ 0.2 2.69 ~ 0.5 1.38 ~ 0.1 2.2 ~ 0.25 1.8 ~ 0.58 1.49 ~ 0.14* Con A 29 ~ 3 32.4 ~ 4.5 31.4 ~ 3.5 38 ~ 5. 9 37. 94 333. 6 S.I. 1.55 ~ 0.1 1.85 ~ 0.2 1.38 ~ 0.1 2.3 ~ 0.1 1.81 ~ 0.5 1.46 ~ 0.15*** PWM 21. 52. 5 224 374. 2 29. 73 37. 84 29. 73. 3 S.I. 1.1 ~ 0.1 1.25 ~ 0.15 1.5 ~ 0.2* 2.52 ~ 0.4* 2.03 ~ 0.7 1.26 ~ 0.1** acontrol group, standard diet *P < 0. 05; **P < 0.01 ; b treatment group, test diet *** P < 0. 001
Analysis of Ivmphocvte subsets bv flow cvtometrv Table 9 shows T-cell relative subset counts and CD4+ : CD8+ ratio pre and post immunisation. When CD4 and CD8 T-cell subsets were analysed there was a significant increase in percentage of CD4 positive cells (p < 0. 05) in both groups and a significant increase in CD8 positive cells in both the control group (p < 0. 05) and test group (p < 0. 001) post immunisation.
When the CD4 + : CD8 + ratio of lymphocytes was examined it was found to be decreased significantly in the control group (p < 0. 001) while remaining constant in the treatment group post immune challenge. When examining age relationships there was a trend towards a decreasing CD4+ : CD8+ ratio with increasing age in the control group prior to immunisation (r =-0. 483. p < 0. 05).
<Desc/Clms Page number 44>
Table 9 T-cell relative subset counts and CD4+: CD8+ ratio pre and post immunisation, MEAN SEM
Pre Post immunisation immunisation standard 3 lara plus b standard lara plus (n = 21) (n = 23) (n = 21) (n = 23) CD4 positive percentage 22. 6). ! 20. 90. 7 25. 1 ~ 1.6 * 24.5 ~ 1.3* CD8 positive percentage 17.2 ~ 0.1 15.4 ~ 1.3 22.3 ~ 1.2* 19.6 ~ 1.6** CD4 CDS ratio 1. 420. 1 !. 570. 1 1.17~ 0.1** 1.43 ~ 0.1 a control group, standard diet P < 0. 05 P < 0. 001 treatment group, test diet The observed difference in SI of PWM stimulated cells from cats fed the supplemented diet (Table 8) suggests that there is a beneficial upregulation of CD2, an activation marker of T-cells.
The results on Table 9 show clearly the beneficial effects of the supplemented diet on the CD4: CD8 ratios of cats post-vaccination. The CD4: CD8 ratio in the supplemented cats was maintained post vaccination compared to the control group. This maintenance is mainly due to an increase in CD4.
These facts show beneficial effects of the supplement upon the immune response of cats.
<Desc/Clms Page number 45>
Example 17 Effects of an Antioxidant Cocktail on Specific Antibody Responses of Young Dogs 'Litters of Labrador and Greyhound Puppies were separated into two age and sex- matched groups.
'One group of each breed had their standard diet (complete, as per the reference
section) supplemented with a cocktail (details given below), the other two groups ZD (one of each breed), remained on an unsupplemented diet.
Antioxidant Cocktail-
alpha-tocopherol 50mg/400kcal ascorbate 20mg/400kcal dry (40mg if wet) beta-carotene 0. 5mg/400kcal lutein 0. 5mg/400kcal taurine 200mg/400kcal dry (500mg if wet) 'Supplement was administered for up to a maximum of four weeks prior to vaccination.
* All of the puppies were vaccinated according to routine vaccination procedures (vaccines included Parvo-virus and Distemper).
* Antibody levels to vaccine antigens were measured for all puppies.
'Some of these results are shown on Figures 4, 5 and 6.
* These results clearly indicate that puppies receiving a supplement of the antioxidant cocktail will mount a faster response to specific antigens such as are introduced via a vaccine or which may be introduced through exposure to an infectious agent.
'These results show that the antioxidant cocktail has a highly beneficial effect on the immune response of young animals.
<Desc/Clms Page number 46>
Example 18 Beneficial Effects of Antioxidant Cocktail on the Maintenance of a Vaccine Response in Adult and Senior Dogs * Two groups of dogs were age, sex and breed matched.
* Both groups were further matched in accordance to when they had previously been vaccinated (prior to the start of the study).
* One group was fed a diet supplemented with an antioxidant cocktail (details given below), the other group remained an unsupplemented control.
Table 10
Antioxidant Content of Diet Supplemented Test Diet Control Diet Vitamin E 52. 41 IU/400 kcal 4. 81 IU/400 kcal Vitamin C 65. 9 mg/400 kcal 2 48 mg/400 kcal Taurine 0. 16% 0.054% Carotenoids -Cis Beta-carotene 11.07 ug/400 kcal < 10. 96 ug/400 kcal -Trans Beta-carotene 33.21 ug/400 kcal 21. 91 ug/400 kcal -Trans Alpha-carotene < 11. 07 ug/400 kcal 10.96 ug/400 kcal - Cis Alpha-carotene < 11. 07 ug/400 kcal < 10.96 ug/400 kcal - Lutein 0. 996 mg/400 kcal 0.877 mg/400 kcal -Lycopene < 11. 07 mg/400 kcal < 10.96 ug/400 kcal -Xeaxanthian 1.22 mg/400 kcal 1.32 mg/400 kcal
* After a period of six months on the supplemented diet the dogs had their 0 circulating anti-adenovirus antibody titre measured. Results are shown on the graph in Figure 7.
* These results show that animals fed a diet containing an antioxidant cocktail are better able to maintain vaccine induced antibodies over time than are unsupplemented dogs.
<Desc/Clms Page number 47>
Example 19 The antioxidant status and oxidative damage in dogs fed a canine dry diet containing an antioxidant cocktail after 8 weeks.
Summary : 'This report contains results (antioxidant status and oxidative damage) from dogs fed a canine dry diet containing an antioxidant cocktail for 8 weeks. Some of the
results were influenced by diet and age. tD * Plasma FRAP and vitamin E levels in the Antioxidant-fed group were significantly higher than in the Control-fed group.
* Plasma vitamin E levels in both the Young Adult and Senior dogs fed the
Antioxidant diet were significantly higher than in their respective Control groups.
MATERIALS & METHODS Animals
1) Type of animals
40 young adult (0.8 to 3.3 years old) and senior (6. 5 to 12.5 years), pure breeds (Labradors, Beagles, West Highland white terrier, Newfoundland, & Golden Retriver), and mixed sex dogs (intact, neutered/spayed) were included in the study.
2) Housing Dogs were grouped in pairs and had access to the outside environment from their pens. All dogs had access to indoors during day and night times. Dogs
<Desc/Clms Page number 48>
from the same treatment group were housed together to prevent cross contamination due to coprophagia (fecal consumption). Temperature was controlled at 22 C with natural light cycle. Dogs were allowed to follow their daily regular exercise routine.
3) Feeding Schdule
All dogs were on a complete and balanced canine dry diet for one week prior to the start of the study. After the one week of adaptation, two-thirds of the dogs remained on the base diet as the control group, while the remaining third was switched over to the test diet. The amount of food fed to each dog was based on the ME equation (1 10 x BW'0. 75 Kcal). The amount of food fed to each dog was adjusted accordingly to maintain bodyweight. All dogs had access to fresh water at all times.
Test Substance The test diet contained the following ingredients that were not added to the control diet.
Ingredients % Added to diet Tomato Pomace 5 Vitamin C 35% 0. 18 Taurine 0. 14 Vitamin E 50% 0. 12 Marigold Meal 10. 04 Trial Design
The study was a longitudinal test design. All dogs were randomly assigned based on z : l breed, sex, age, body weight and health status.
Groups n's per Age (yrs) Diets Test Period group
<Desc/Clms Page number 49>
Control 26 5.5 : t 4. 3 Control Diet 8 weeks (A, B, E, F) (w/o antioxidant cocktail) Test 14 5.9 4. 4 Antioxidant Cocktail Diet 8 weeks (C, G) Same dogs as the above table, however, they were broken down by age.
Groups n's per Avg age w/m each Diets Test Period group group (years SD) Young Adult Control 12 1.2 08 Control Diet 8 weeks (A, B) Young Adult Test 6 1. 0 : t 0. 1 Antioxidant 8 weeks (C) Cocktail Diet Senior Control 14 9. 3 ~ 2. 0 Control Diet 8 weeks (E, F) Senior Test 8 9.5 ~ 1. 5 Antioxidant 8 weeks (G) Cocktail Diet Blood and saliva biomarkers : Bloods were collected from each dog to measure the following parameters at 8 weeks after the treatment.
Antioxidants/DamageDescription Plasma vitamin E Fat soluble antioxidant Plasma FRAP/FRASC A measure of"Antioxidant Power"in plasma & ascorbic acid level Statistics Analyses were determined for all dogs for all parameters by unequal n's Tukey's post hoc test for statistical significance between treatment at p < 0.05. Data are expressed as group means SD.
Figure 8: The measurement of ferric reducing ability of plasma (FRAP) that measures the"antioxidant capacity"in dogs fed a canine dry diet containing an antioxidant cocktail ! for a period of 8 weeks. (Control, n=26; Test, n=14). *Represents significant differences from the Control group, p < 0.05.
<Desc/Clms Page number 50>
The measurement of plasma "antioxidant capacity" in the Test group was I if I significantly higher than in the Control group after 8 weeks of treatment. s Figure 9: The measurement of plasma vitamin E levels in dogs fed a canine dry diet containing an antioxidant cocktail for a period of 8 weeks. (Control, n=26; Test, n=14). *Represents significant differences from the Control group, p < 0. 05.
Plasma vitamin E level in the Test group was significantly higher than in the
Control group after 8 weeks of treatment.
Reference Diet Section Nutritionally complete diet A complete diet for foodstuff, especially a nutritionally complete petfood (or diet) is a diet which meets all the nutritional requirements of the individual animal's lifestyle and lifestage.
The diet or foodstuff can be made according to any method known in the art, such as in Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chapter by A.
Rainsbird, entitled"A Balanced Diet"in pages 57 to 74, Pergoren Press Oxford.
0 The following shows a composition of a complete balanced diet according to the Examples.
Ingredient Inclusion Rice 24.9% Whole corn 18.8% Whole grain wheat 12.2%
<Desc/Clms Page number 51>
5 10
Chicken by-product meat 18. 7% Corn gluten meal 9.5% Brewers yeast 1.7% Dried egg 0.8% Non-iodinised salt 0.7% Vitamin premix 3.4% Sunflower oil 0.5% Beef tallow 4. 9% Poultry viscera 4. 4% Analytical profile-moisture 8. 2%, protein 26.4%, fat 10.4%, ash 7. t%, fibre 2.2% (the remainder being made up of nitrogen-free extract (mainly carbohydrate)).
Claims (41)
- Claims: 1. Use of vitamin E, lutein and beta-carotene, in the manufacture of a dogor cat foodstuff, diet or supplement for strengthening the immune response of a ZD cat or a dog. tD*
- 2. Use, as claimed in claim 1, wherein the vitamin E is present at a concentration of 25IU/400kcal or above.
- 3. Use, as claimed in claim 1 or claim 2, wherein the lutein is present at a concentration of O. Olmg/400kcal or above.
- 4. Use, as claimed in any one of claims 1 to 3, wherein the beta-carotene is present at a concentration of O. Olmg/400kcal or above.
- 5. Use, as claimed in any one of claims 1 to 4, wherein the foodstuff, diet or supplement further comprises vitamin C and/or taurine.
- 6. Use, as claimed in claim 5, wherein the taurine is present at a concentration of 80mg/400kcal or above.
- 7. Use, as claimed in any one of claims 1 to 6, wherein the foodstuff, diet or supplement further comprises a further carotenoid.
- 8. Use, as claimed in any one of claims 1 to 7, for treating or assisting a cat or dog in response to the immune challenge of vaccination.
- 9. A method for increasing the plasma vitamin E level in a cat or dog, the method<Desc/Clms Page number 53>comprising the step of administering to said cat or dog, an amount of Vitamin E sufficient to increase the plasma vitamin E level.
- 10. A method, as claimed in claim 1, further comprising administering to said cat or dog, an amount of vitamin C.
- 11. A method, as claimed in claim 1 or claim 2, further comprising administering to said cat or dog, an amount of taurine.
- 12. A method, as claimed in claim 1 or claim 2, further comprising administering to said cat or said dog, an amount of vitamin C and an amount of taurine.
- 13. A method as claimed in any one of claims 1 to 5, further comprising administering to said cat or dog, an amount of a carotenoid.
- 14. A method as claimed in any one of claims 2 to 6, wherein the components are administered simultaneously, separately, or sequentially.
- 15. A dog or cat foodstuff which delivers to said animal, a concentration of ingredients sufficient to increase the antioxidant status of the animal.
- 16. A dog or cat foodstuff which provides a concentration of vitamin E at a level of 25IU/400kcal diet or above.
- 17. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of vitamin C at a level of 10mg/400kcal or above.
- 18. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of taurine at a level of 80mg/400kcal or above.<Desc/Clms Page number 54>
- 19. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of vitamin C at a level of 10mg/400kcal, or above and which provides a concentration of taurine at a level of 80mg/400kcal or above.
- 20. A dog or cat foodstuff as claimed on any one of claims 7 to 11, which provides a concentration of a carotenoid.
- 21. A dog or cat foodstuff as claimed in any one of claims 7 to 12. for use in the prevention or treatment of low antioxidant status in a dog or cat.
- 22. A dog or cat foodstuff as claimed in any one of claims 7 to 12, for use in the prevention or treatment of any disorder which has a component of stress.
- 23. A dog or cat foodstuff as claimed in claim 14, wherein the disorder is any one or more of; cancer, ageing, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure, neurodegcnerative disease or compromised immunity.
- 24. A dog or cat foodstuff, as claimed in any one of claims 7 to 14 for use in treating or assisting a cat or a dog in response to an immune challenge.
- 25. A foodstuff as claimed in claim 16, wherein the immune challenge is vaccination.
- 26. A method for preventing or treating a dog or cat suffering from a disorder which has a component of oxidative stress comprising feeding to said dog or cat a foodstuff as claimed in any one of claims 7 to 12.<Desc/Clms Page number 55>
- 27. A method of maintaining optimising or boosting an immune response to an immunological challenge in an animal comprising feeding said animal a foodstuff as 0 1- t : l claimed in any one of claims 7 to 12.
- 28. Use of vitamin, in the manufacture of a medicament for the prevention or treatment of low antioxidant status in a dog or cat.
- 29. Use of vitamin E, in the manufacture of a clinical diet for the prevention or treatment of any disorder which has a component of oxidative stress.
- 30. Use of vitamin E, as claimed in claim 21, for maintaining, optimising or boosting an immune response, in a cat or a dog, in response to an immunological challenge.
- 31. Use of vitamin E, incorporated into a foodstuff as an in vivo antioxidant, in a dog or cat.
- 32. A method for making a foodstuff as claimed in any one of claims 7 to 14 or 21, the method comprising mixing together at least two ingredients of the foodstuff.
- 33. A dog or cat foodstuff comprising vitamin C at a concentration of ZD 0 15mg/400kcal or above.
- 34. Use of vitamin C in the manufacture of a dog or cat foodstuff for the prevention or treatment of a disorder which has a component of oxidative stress.
- 35. Use of vitamin C as claimed in claim 26, wherein the disorder is any one or more of, cancer, ageing, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure, neurodegenerative disease or compromised immunity.<Desc/Clms Page number 56>
- 36. Use of vitamin C as claimed in claim 26 for treating or assisting in response to an immunological challenge
- 37. A method for prevention or treatment in a cat or a dog of a disorder which has a component of oxidative stress comprising feeding said cat or dog a foodstuff as claimed in claim 25.
- 38. A dog or cat foodstuff as claimed in claim 7 which comprises : ZD alpha-tocopherol ascorbate beta-carotene lutein and taurine.
- 39. A dog or cat foodstuff as claimed in claim 30 which also comprises: lycopene
- 40. A dog or cat foodstuff as claimed in claim 30, wherein the components present as follows:alpha-tacopherol : from 25IU/400kcal ascorbate: from 5mg/kcal beta-carotene: from O. Olmg/400kcal lutein: from 0. 05mg/400kcaJ taurine: from 80mg/400kcal
- 41. A dog or a cat foodstuff as claimed in claim 32 further comprising lycopene at a concentration of from O. Olmg/400kcal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902051.3A GB9902051D0 (en) | 1999-01-29 | 1999-01-29 | Compositions and methods |
GBGB9928549.6A GB9928549D0 (en) | 1999-12-02 | 1999-12-02 | Compositions and methods |
GB0118809A GB2366179B (en) | 1999-01-29 | 2000-01-31 | Antioxidant compositions and methods for companion animals |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0227967D0 GB0227967D0 (en) | 2003-01-08 |
GB2380130A true GB2380130A (en) | 2003-04-02 |
GB2380130B GB2380130B (en) | 2003-07-23 |
Family
ID=27256243
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0227967A Expired - Lifetime GB2380130B (en) | 1999-01-29 | 2000-01-31 | Antioxidant compositions and methods for companion animals |
GB0303606A Expired - Lifetime GB2382974B (en) | 1999-01-29 | 2000-01-31 | Antioxidant compositions and methods for companion animals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0303606A Expired - Lifetime GB2382974B (en) | 1999-01-29 | 2000-01-31 | Antioxidant compositions and methods for companion animals |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB2380130B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0848955A1 (en) * | 1996-12-18 | 1998-06-24 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals comprising an ascorbic acid derivative |
-
2000
- 2000-01-31 GB GB0227967A patent/GB2380130B/en not_active Expired - Lifetime
- 2000-01-31 GB GB0303606A patent/GB2382974B/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0848955A1 (en) * | 1996-12-18 | 1998-06-24 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals comprising an ascorbic acid derivative |
Also Published As
Publication number | Publication date |
---|---|
GB0303606D0 (en) | 2003-03-19 |
GB2382974A (en) | 2003-06-18 |
GB2380130B (en) | 2003-07-23 |
GB0227967D0 (en) | 2003-01-08 |
GB2382974B (en) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2360680C (en) | Antioxidant compositions and methods for companion animals | |
AU783103B2 (en) | Lara for use in reduction of DNA damage | |
AU2006279429B2 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
AU2005321958B2 (en) | Compositions and methods for improving kidney function | |
US20040047898A1 (en) | Antioxidant compositions and methods for companion animals | |
RU2376035C2 (en) | Methods and compositions for prevention and treatment of kidney diseases in cats | |
EP3367814B1 (en) | Synergistically-effective antioxidant composition for pets | |
GB2367489A (en) | Anti-oxidant compositions for companion animals | |
AU2004200161B2 (en) | Antioxident compositions and methods for companion animals | |
GB2380130A (en) | Antioxidant compositions for companion animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) |
Free format text: REGISTERED BETWEEN 20090205 AND 20090211 |
|
PE20 | Patent expired after termination of 20 years |
Expiry date: 20200130 |